schliessen

Filtern

 

Bibliotheken

Phase I study of a Neisseria meningitidis liposomal vaccine containing purified outer membrane proteins and detoxified lipooligosaccharide

► Immunogenicity of outer membrane proteins not enhanced by combining with liposomes. ► Liposomes were an effective formulation for the presentation of lipooligosaccharides. ► Truncated L8-5 LOS induced antibodies bactericidal for strains with full length LOS. ► The strongest bactericidal antibody r... Full description

Journal Title: Vaccine 2012, Vol.30(4), pp.712-721
Main Author: Zollinger, Wendell D
Other Authors: Babcock, Janiine G , Moran, Elizabeth E , Brandt, Brenda L , Matyas, Gary R , Wassef, Nabila M , Alving, Carl R
Format: Electronic Article Electronic Article
Language: English
Subjects:
ID: ISSN: 0264-410X ; E-ISSN: 1873-2518 ; DOI: 10.1016/j.vaccine.2011.11.084
Link: https://www.sciencedirect.com/science/article/pii/S0264410X11018809
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: elsevier_sdoi_10_1016_j_vaccine_2011_11_084
title: Phase I study of a Neisseria meningitidis liposomal vaccine containing purified outer membrane proteins and detoxified lipooligosaccharide
format: Article
creator:
  • Zollinger, Wendell D
  • Babcock, Janiine G
  • Moran, Elizabeth E
  • Brandt, Brenda L
  • Matyas, Gary R
  • Wassef, Nabila M
  • Alving, Carl R
subjects:
  • Neisseria Meningitidis
  • Vaccine
  • Liposome
  • Lipooligosaccharide
  • Human
  • Medicine
  • Biology
  • Veterinary Medicine
  • Pharmacy, Therapeutics, & Pharmacology
ispartof: Vaccine, 2012, Vol.30(4), pp.712-721
description: ► Immunogenicity of outer membrane proteins not enhanced by combining with liposomes. ► Liposomes were an effective formulation for the presentation of lipooligosaccharides. ► Truncated L8-5 LOS induced antibodies bactericidal for strains with full length LOS. ► The strongest bactericidal antibody response was induced by the L8-5 LOS. Purified outer membrane proteins and purified deacylated lipooligosaccharide (dLOS) were formulated for use as a vaccine in three formulations for clinical use. The three vaccine formulations included (1) purified outer membrane proteins (OMPs) and L8-5 dLOS adsorbed to aluminum hydroxide; (2) purified OMPs and L8-5 dLOS incorporated into liposomes; and (3) purified OMPs and L7 dLOS incorporated into proteoliposomes. The vaccines were compared for immunogenicity and safety in a phase 1clinical study. Ten adult volunteers were vaccinated with each of the three vaccine formulations. Two 50 μg doses were given...
language: eng
source:
identifier: ISSN: 0264-410X ; E-ISSN: 1873-2518 ; DOI: 10.1016/j.vaccine.2011.11.084
fulltext: fulltext
issn:
  • 0264-410X
  • 0264410X
  • 1873-2518
  • 18732518
url: Link


@attributes
ID1266817574
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordiddoi_10_1016_j_vaccine_2011_11_084
sourceidelsevier_s
recordidTN_elsevier_sdoi_10_1016_j_vaccine_2011_11_084
sourcesystemPC
dbid
0--K
1--M
2.FO
3.~1
41B1
51P~
61RT
71~.
8457
94G.
107-5
118P~
129JM
13AABNK
14AAEDT
15AAKOC
16AAOAW
17AAQFI
18AARKO
19ABBQC
20ABFNM
21ABKYH
22ABMZM
23ABRWV
24ABYKQ
25ACDAQ
26ACIUM
27ACRLP
28AEKER
29AEVXI
30AEXOQ
31AFKWA
32AFTJW
33AFXIZ
34AGEKW
35AGHFR
36AGUBO
37AGYEJ
38AHHHB
39AIKHN
40AITUG
41AJBFU
42AJOXV
43AJRQY
44AJUYK
45AMFUW
46ANZVX
47BLXMC
48BNPGV
49CJTIS
50EO8
51EO9
52EP2
53EP3
54FDB
55FGOYB
56FIRID
57FNPLU
58G-Q
59GBLVA
60HEJ
61HLV
62HMG
63HMK
64HMO
65J1W
66KOM
67LCYCR
68LUGTX
69O9~
70OAUVE
71OK0
72P-8
73P-9
74PC.
75Q38
76QYZTP
77R2-
78RPZ
79SAB
80SAE
81SCC
82SDF
83SDG
84SDP
85SES
86SEW
87SIN
88SNL
89SSH
90SSI
91SSZ
92SVS
93T5K
94UV1
95Z5R
96~G-
pqid920801578
galeid276591897
display
typearticle
titlePhase I study of a Neisseria meningitidis liposomal vaccine containing purified outer membrane proteins and detoxified lipooligosaccharide
creatorZollinger, Wendell D ; Babcock, Janiine G ; Moran, Elizabeth E ; Brandt, Brenda L ; Matyas, Gary R ; Wassef, Nabila M ; Alving, Carl R
ispartofVaccine, 2012, Vol.30(4), pp.712-721
identifier
subjectNeisseria Meningitidis ; Vaccine ; Liposome ; Lipooligosaccharide ; Human ; Medicine ; Biology ; Veterinary Medicine ; Pharmacy, Therapeutics, & Pharmacology
description► Immunogenicity of outer membrane proteins not enhanced by combining with liposomes. ► Liposomes were an effective formulation for the presentation of lipooligosaccharides. ► Truncated L8-5 LOS induced antibodies bactericidal for strains with full length LOS. ► The strongest bactericidal antibody response was induced by the L8-5 LOS. Purified outer membrane proteins and purified deacylated lipooligosaccharide (dLOS) were formulated for use as a vaccine in three formulations for clinical use. The three vaccine formulations included (1) purified outer membrane proteins (OMPs) and L8-5 dLOS adsorbed to aluminum hydroxide; (2) purified OMPs and L8-5 dLOS incorporated into liposomes; and (3) purified OMPs and L7 dLOS incorporated into proteoliposomes. The vaccines were compared for immunogenicity and safety in a phase 1clinical study. Ten adult volunteers were vaccinated with each of the three vaccine formulations. Two 50 μg doses were given...
languageeng
source
version8
lds50peer_reviewed
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
backlink$$Uhttps://www.sciencedirect.com/science/article/pii/S0264410X11018809$$EView_record_in_ScienceDirect_(Access_to_full_text_may_be_restricted)
search
creatorcontrib
0Zollinger, Wendell D
1Babcock, Janiine G
2Moran, Elizabeth E
3Brandt, Brenda L
4Matyas, Gary R
5Wassef, Nabila M
6Alving, Carl R
titlePhase I study of a Neisseria meningitidis liposomal vaccine containing purified outer membrane proteins and detoxified lipooligosaccharide
description

► Immunogenicity of outer membrane proteins not enhanced by combining with liposomes. ► Liposomes were an effective formulation for the presentation of lipooligosaccharides. ► Truncated L8-5 LOS induced antibodies bactericidal for strains with full length LOS. ► The strongest bactericidal antibody response was induced by the L8-5 LOS.

Purified outer membrane proteins and purified deacylated lipooligosaccharide (dLOS) were formulated for use as a vaccine in three formulations for clinical use. The three vaccine formulations included (1) purified outer membrane proteins (OMPs) and L8-5 dLOS adsorbed to aluminum hydroxide; (2) purified OMPs and L8-5 dLOS incorporated into liposomes; and (3) purified OMPs and L7 dLOS incorporated into proteoliposomes. The vaccines were compared for immunogenicity and safety in a phase 1clinical study. Ten adult volunteers were vaccinated with each of the three vaccine formulations. Two 50

μg doses were given...

subject
0Neisseria Meningitidis
1Vaccine
2Liposome
3Lipooligosaccharide
4Human
5Medicine
6Biology
7Veterinary Medicine
8Pharmacy, Therapeutics, & Pharmacology
general
0English
1Elsevier Ltd
210.1016/j.vaccine.2011.11.084
3ScienceDirect (Elsevier)
4ScienceDirect Journals (Elsevier)
sourceidelsevier_s
recordidelsevier_sdoi_10_1016_j_vaccine_2011_11_084
issn
00264-410X
10264410X
21873-2518
318732518
rsrctypearticle
creationdate2012
addtitleVaccine
searchscope
0elsevier_full
1elsevier2
scope
0elsevier_full
1elsevier2
lsr44$$EView_record_in_ScienceDirect_(Access_to_full_text_may_be_restricted)
tmp01ScienceDirect Journals (Elsevier)
tmp02
0--K
1--M
2.FO
3.~1
41B1
51P~
61RT
71~.
8457
94G.
107-5
118P~
129JM
13AABNK
14AAEDT
15AAKOC
16AAOAW
17AAQFI
18AARKO
19ABBQC
20ABFNM
21ABKYH
22ABMZM
23ABRWV
24ABYKQ
25ACDAQ
26ACIUM
27ACRLP
28AEKER
29AEVXI
30AEXOQ
31AFKWA
32AFTJW
33AFXIZ
34AGEKW
35AGHFR
36AGUBO
37AGYEJ
38AHHHB
39AIKHN
40AITUG
41AJBFU
42AJOXV
43AJRQY
44AJUYK
45AMFUW
46ANZVX
47BLXMC
48BNPGV
49CJTIS
50EO8
51EO9
52EP2
53EP3
54FDB
55FGOYB
56FIRID
57FNPLU
58G-Q
59GBLVA
60HEJ
61HLV
62HMG
63HMK
64HMO
65J1W
66KOM
67LCYCR
68LUGTX
69O9~
70OAUVE
71OK0
72P-8
73P-9
74PC.
75Q38
76QYZTP
77R2-
78RPZ
79SAB
80SAE
81SCC
82SDF
83SDG
84SDP
85SES
86SEW
87SIN
88SNL
89SSH
90SSI
91SSZ
92SVS
93T5K
94UV1
95Z5R
96~G-
startdate20120101
enddate20121231
lsr40Vaccine, 2012, Vol.30 (4), pp.712-721
doi10.1016/j.vaccine.2011.11.084
citationpf 712 pt 721 vol 30 issue 4
lsr30VSR-Enriched:[pqid, date, galeid]
sort
titlePhase I study of a Neisseria meningitidis liposomal vaccine containing purified outer membrane proteins and detoxified lipooligosaccharide
authorZollinger, Wendell D ; Babcock, Janiine G ; Moran, Elizabeth E ; Brandt, Brenda L ; Matyas, Gary R ; Wassef, Nabila M ; Alving, Carl R
creationdate20120000
lso0120120000
facets
frbrgroupid8082119226601092023
frbrtype5
newrecords20190904
languageeng
topic
0Neisseria Meningitidis
1Vaccine
2Liposome
3Lipooligosaccharide
4Human
5Medicine
6Biology
7Veterinary Medicine
8Pharmacy, Therapeutics, & Pharmacology
collectionScienceDirect (Elsevier)
prefilterarticles
rsrctypearticles
creatorcontrib
0Zollinger, Wendell D
1Babcock, Janiine G
2Moran, Elizabeth E
3Brandt, Brenda L
4Matyas, Gary R
5Wassef, Nabila M
6Alving, Carl R
jtitleVaccine
creationdate2012
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
aulast
0Zollinger
1Babcock
2Moran
3Brandt
4Matyas
5Wassef
6Alving
aufirst
0Wendell D
1Janiine G
2Elizabeth E
3Brenda L
4Gary R
5Nabila M
6Carl R
auinitW
auinit1W
au
0Zollinger, Wendell D
1Babcock, Janiine G
2Moran, Elizabeth E
3Brandt, Brenda L
4Matyas, Gary R
5Wassef, Nabila M
6Alving, Carl R
atitlePhase I study of a Neisseria meningitidis liposomal vaccine containing purified outer membrane proteins and detoxified lipooligosaccharide
jtitleVaccine
risdate2012
volume30
issue4
spage712
epage721
pages712-721
issn0264-410X
eissn1873-2518
formatjournal
genrearticle
ristypeJOUR
abstract

► Immunogenicity of outer membrane proteins not enhanced by combining with liposomes. ► Liposomes were an effective formulation for the presentation of lipooligosaccharides. ► Truncated L8-5 LOS induced antibodies bactericidal for strains with full length LOS. ► The strongest bactericidal antibody response was induced by the L8-5 LOS.

Purified outer membrane proteins and purified deacylated lipooligosaccharide (dLOS) were formulated for use as a vaccine in three formulations for clinical use. The three vaccine formulations included (1) purified outer membrane proteins (OMPs) and L8-5 dLOS adsorbed to aluminum hydroxide; (2) purified OMPs and L8-5 dLOS incorporated into liposomes; and (3) purified OMPs and L7 dLOS incorporated into proteoliposomes. The vaccines were compared for immunogenicity and safety in a phase 1clinical study. Ten adult volunteers were vaccinated with each of the three vaccine formulations. Two 50

μg doses were given...

pubElsevier Ltd
doi10.1016/j.vaccine.2011.11.084
lad01Vaccine
date2012-01-17